Openbookopenbook
Equity
Caris Life Sciences, Inc. Common Stock(CAI)
USD --+0.00%
Reward61Moderate
Risk30Moderate
📊75%Data
Thin -8% profit margin · Revenue growing 125% YoY
CAI
+0.0 · +0.00%
USD · NASDAQ
Caris Life Sciences, Inc. Common Stock | Healthcare
Growth Machine
Market Cap:5.02Bn
ℹ️
Reward Rating
61
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
30
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on CAI to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $29.69.

What is Caris Life Sciences, Inc. Common Stock?

, an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.

CAI · Verdict

Solid reward · low risk

CAI stands out on volatility and growth, but watch the valuation signal.

Based on 88% data coverage

CAI · Verdict

What’s working & what to watch

Strengths 3

  • Volatility95/100

    Top decile vs peers

  • Growth83/100

    Rev +46.5% CAGR · earnings +18.8%

  • Balance sheet76/100

    Current ratio 7.85

Watchouts 2

  • Valuation44/100

    P/E 33.6× · PEG 0.20

  • Cash flow45/100

    8% free-cash-flow margin

Model-based scoring. For information only — not financial advice.

What is Caris Life Sciences, Inc. Common Stock?

, an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 5.02B.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Profitability metrics are mixed — margins may be under pressure.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (61)

The scoring profile indicates moderate reward potential, with growth and momentum as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap5.02B
P/E RatioN/A
Dividend YieldN/A
52 Week High42.5
52 Week Low16.28
Last AnnualDecember
IPO Date6/18/2025
IncorporatedUSA
Shares Outstanding283M
No. of Employees1,846
IndustryBiotechnology
ExchangeNASDAQ
BetaN/A
CurrencyUSD
Websitewww.carislifesciences.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.